TickerKhojComparison · NSE · data 2026-11-03
Indegene Limited vs NATCO Pharma Limited
In plain words
Size: NATCO Pharma Limited is about 1.1 times the market value of Indegene Limited.
Valuation (P/E): Indegene Limited 36.4 vs NATCO Pharma Limited 12.4.
Return on equity: NATCO Pharma Limited 16.9% vs Indegene Limited 13.9%.
Profit growth over 3 years: NATCO Pharma Limited 25.6% a year vs Indegene Limited 14.7% a year.
Debt to equity: NATCO Pharma Limited 0.08 vs Indegene Limited 0.05.
Differences in the numbers, not a recommendation of either stock.
Side by side
| INDGN | NATCOPHARM | |
|---|---|---|
| Price | ₹619.4 | ₹785.75 |
| Market cap | ₹14,161 cr | ₹15,350 cr |
| P/E | 36.4 | 12.4 |
| P/B | 4.4 | — |
| ROE | 13.9% | 16.9% |
| ROCE | 15.9% | 15.6% |
| Debt / equity | 0.05 | 0.08 |
| Operating margin | 12.4% | 24.6% |
| Dividend yield | 0.38% | 0.57% |
| Sales growth, 3 years (yearly) | 15.0% | 14.5% |
| Profit growth, 3 years (yearly) | 14.7% | 25.6% |
| 1-year return | 11.4% | -5.0% |
| Revenue, last 12 months | ₹4,131 cr | ₹3,485 cr |
| Net profit, last 12 months | ₹411 cr | ₹1,144 cr |
| Latest quarter | Sept 2026 | Jun 2026 |
| Quarter net profit | ₹112 cr | ₹207 cr |
| Quarter profit vs a year earlier | +10.0% | -57.0% |
| Promoter holding | — | 49.39% |
| Health check | Strong (7.3/10) | Strong (6.8/10) |
Common questions
Which has a higher P/E, Indegene Limited or NATCO Pharma Limited?
Indegene Limited trades at the higher P/E (36.4 against 12.4). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
NATCO Pharma Limited (16.9% against 13.9%).
Which carries more debt?
NATCO Pharma Limited has the higher debt-to-equity ratio (0.08 against 0.05).